GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today ...
Zacks Investment Research on MSN
Coherus Oncology (CHRS) reports Q4 loss, misses revenue estimates
Coherus Oncology (CHRS) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.31. This compares to a loss of $0.28 per share a year ago. These figures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results